There are few randomized controlled trial data to confirm that improved homogeneity with simple intensity-modulated radiotherapy (IMRT) decreases late breast tissue toxicity. The Cambridge Breast IMRT trial investigated this hypothesis, and the 5-year results are reported.
INTRODUCTION
Radiation therapy (RT) has an established role in the management of early-stage breast cancer.
1 However, some patients develop RT-related complications, including breast fibrosis, breast shrinkage, poor breast cosmesis, and telangiectasia, which contribute to their psychological morbidity.
2 With improving breast cancer survival, there is increasing focus on reducing treatment-related complications. The use of advanced RT techniques like intensitymodulated RT (IMRT) offers an opportunity to reduce RT-related complications. The overall aim of IMRT is to improve coverage of the RT target and/or to minimize dose to surrounding normal tissues. The term IMRT covers a spectrum of techniques, ranging from relatively simple to highly complex. For the majority of patients treated with breast RT, it seems that a simple form of IMRT may be the most appropriate technique. This simple IMRT uses additional irradiation fields to smooth out the dose to the breast (ie, target). More complex IMRT techniques can produce a large volume of low-dose radiation to surrounding tissues. As a result, complex IMRT tends to be restricted to cases in which a steep dose gradient is required (eg, in patients with pectus excavatum, who would otherwise receive unacceptably high dose to surrounding organs at risk [ie, lungs and heart]).
Studies have shown improved dose homogeneity across the breast with the use of simple and complex IMRT, 3, 4 and it would be expected that improved dose homogeneity would reduce late breast tissue toxicity. However, there are few randomized controlled trial data to confirm the advantage of IMRT over standard RT in breast cancer.
5-7 Donovan et al 5 showed reduction in late breast tissue toxicity with IMRT among women who were judged to be at higher than average risk of radiation-induced toxicity based on breast size and/or breast shape. Worldwide, the practice of whole-breast RT is gradually shifting from standard two-dimensional RT to IMRT. 8, 9 However, skeptics have pointed out that breast IMRT is being clinically implemented with a paucity of data on its long-term benefits. 10, 11 The large randomized Cambridge Breast IMRT trial was designed to investigate whether the correction of dose inhomogeneity using simple IMRT would decrease late breast tissue toxicity.
12 It included women with all breast sizes, and the interim results at 2 years showed statistically significant reduction in the risk of telangiectasia with IMRT as compared with standard RT.
6 However, the 2-year time point was considered insufficient for patients to experience their final level of toxicity and demonstrate the full benefits of IMRT. The preplanned long-term results of the trial at 5 years are reported here to determine if improved dose homogeneity with simple IMRT translates into clinical benefits of reduced late breast tissue toxicity.
PATIENTS AND METHODS
The 
Study Population
Women with operable unilateral, histologically confirmed invasive breast cancer (T1-3, N0-1, M0) or ductal carcinoma in situ requiring RT after breast-conservation surgery were eligible for the trial (Fig 1) . All patients with T1-3, N0-1, M0 invasive breast cancer/DCIS requiring RT. Breast conservation surgery with complete tumor excision.
Approached to participate in trial (N = 1,283)
Recruited to trial (n = 1,145) Dosimetry with standard breast plan:
ICRU recommendations
Tumor-related (n = 52) Breast cancer-related (n = 21) death Non-breast cancer-related (n = 13) death Local recurrence (n = 11) Contralateral new primary (n = 5) Alive with metastatic (n = 1) disease New cancer (n = 1) Patient-related (n = 115) Moved out of area (n = 15) Withdrew consent (n = 11) Transport issues (n = 14) Not known (n = 5) Social issues including (n = 14) work commitment/carer Unable to contact (n = 11) Elective reconstruction/ (n = 3) implants Unwell to attend (n = 9) Patient choice: reason (n = 33) not stated Tumor-related (n = 54) Breast cancer-related (n = 17) death Non-breast cancer-related death (n = 20) Local recurrence (n = 6) Contralateral new primary (n = 5) Alive with metastatic (n = 2) disease New cancer (n = 4) Patient-related (n = 129) Moved out of area (n = 13) Withdrew consent (n = 16) Transport issues (n = 19) Not known (n = 6) Social issues including (n = 19) work commitment/carer Unable to contact (n = 10) Elective reconstruction/ (n = 6) implants Unwell to attend (n = 9) Patient choice: reason (n = 31) not stated invasive breast cancer underwent sentinel node biopsy and/or axillary clearance (if lymph node positive). Other eligibility criteria included age Ͼ 18 years, no history of contralateral breast cancer, no malignancy in the previous 5 years (except skin basal cell or squamous carcinoma or in situ carcinoma of cervix), and availability for follow-up. All patients provided written informed consent. A total of 1,145 patients were recruited.
Sample Size Calculation
The sample size was based on a standard event rate of 40% in the control arm at 2 years. The difference to be detected was estimated to be 10%, with a hazard ratio of 0.7. Assuming a minimal average follow-up of 2 years, 80% power, and type I error of 0.05, 358 patients and 125 events were required in each of the randomly assigned arms. This sample size was increased by 10% to adjust for possible loss to follow-up by 2 years.
Random Assignment
A standard RT plan consisting of paired wedged tangents was produced for all trial patients. Patients with satisfactory dose homogeneity (29%) were not randomly assigned but instead treated with standard RT and observed for the same follow-up as the randomly assigned patients. Patients whose plan had significant dose inhomogeneity, defined as Ն 2 cm 3 volume receiving Ͼ 107% of the prescribed dose, were randomly assigned between standard RT (control arm) and forward-planned field-in-field dose homogenization IMRT (simple IMRT; interventional arm; Fig 2) . Random assignment was performed using permuted blocks of mixed block size and was stratified for T stage and adjuvant therapy. Patients were informed of their randomly assigned arm if they enquired at the time of RT treatment.
RT Technique
Patients in the control arm were treated with wedged tangential fields to the breast, and patients in the interventional arm were replanned with a simple IMRT technique to reduce the volume receiving Ͼ 107% and Ͻ 95% of the prescribed dose. The full details of the RT planning technique are described in the Appendix (online only).
All patients were treated to a dose of 40 Gy in 15 fractions, 5 days per week over 3 weeks, with 6-MV photons prescribed to the ICRU (International Commission on Radiation Units) 50 reference point. Mixed energies of 6-and 15-MV photons were used in patients with large breast separation. Nodal irradiation and sequential tumor bed boost were administered according to local protocol. After completion of RT, all patients were treated similarly irrespective of their allocated treatment arm.
Outcome Measures: Breast Toxicity End Points
Patients were assessed at 2 and 5 years after completion of RT using serial photographs and clinical examination. The primary outcome of the study was photographic assessment of late cosmetic effects, and the secondary outcome was clinical assessment of breast late normal tissue changes (induration, telangiectasia, and breast edema). Toxicity assessors were unaware of a patient's treatment arm. This article reports these end points at 5 years from completion of RT.
Photographic assessment. Frontal photographs of both breasts were taken after primary surgery and before RT (baseline) and repeated at 2 and 5 years post-RT. Two photographs were taken: one with the hands resting on the hips, and the other with the arms raised above the head. The 5-year photographs were compared with postoperative baseline photographs for RTassociated breast shrinkage and scored on a validated three-point scale (1, none/minimal; 2, mild; 3, marked). A multidisciplinary team of seven clinicians (four oncologists, one radiographer, one surgeon, and one breast care nurse) were involved in photographic assessment, with a panel of three being present at any one time. This method has been validated and shown to be quicker than using three independent scorers with rescoring of discrepancies and final resolution through discussion and was used to score the UK START (Standardisation of Breast Radiotherapy) trial photographs. 13 The interobserver variability of this assessment has been validated before by our group.
6
The panel also scored overall cosmesis on photographs taken at 5 years by assessing the global breast appearance (looking at breast shrinkage, breast distortion, and skin changes), independent of baseline cosmetic appearance. The overall breast appearance (cosmesis) was scored using a three-point score (good, moderate, and poor cosmesis) as per the United Kingdom FAST (Faster Radiotherapy for Breast Cancer Patients) study 14 and Royal Marsden Hospital IMRT trial, 5 with moderate to poor scores regarded as suboptimal cosmesis. In addition, postoperative baseline photographs were scored for surgical cosmesis using a three-point score (good, moderate, and poor). Other computerized methods for photo scoring, like BCCT (breast cancer conservative treatment).core software (Breast Research Group, Porto, Portugal), 15 were not available at the time of study design and hence not used in this study.
Clinical assessment. The treated breast was assessed at 5 years for breast edema, skin telangiectasia, breast shrinkage, pigmentation changes, and palpable induration. Each of these end points was graded from 0 to 3 (none, a little, quite a bit, very much) on the scale used in the START trials. 16, 17 All 5-year clinical assessments were performed by a single trained research radiographer (J.S.W.).
The planned photographic and clinical assessments were not performed in cases of local tumor relapse, metastatic disease, new cancer diagnosis, additional breast surgery, poor health, and patient refusal. Patients who were unable to attend the 5-year follow-up appointment were contacted via telephone to assess their well being.
Statistical Analysis
The baseline demographics for patients with 5-year follow-up data were compared using the student t test, Pearson's 2 test, and Fisher's exact test for heterogeneity and trend. Toxicity end points were compared between the randomly assigned patients on univariate analysis using polychotomous logistic regression analysis. Stepwise multivariate polychotomous logistic regression was used to analyze the patient-and treatment-related factors that were significantly associated with late toxicity after RT on univariate analysis (P Ͻ .1). Univariate and multivariate odds ratios (ORs) were generated.
Baseline surgical cosmesis was an important determinant factor for breast toxicity end points at 2 years in this trial. 6 Hence, data from all trial patients (those randomly assigned and not randomly assigned) were used to assess the effect of baseline (pre-RT) surgical cosmesis on late toxicity end points at 5 years using polychotomous logistic regression. In addition, baseline surgical cosmesis was included in the multivariate analysis of final overall cosmesis between the randomly assigned patients.
The 5-year locoregional recurrence (LRR) and overall survival (OS) rates were compared between randomly assigned patients using the MantelHaenszel (log-rank) test. The length of follow-up or time to an event was measured from the date of random assignment, and analysis was performed according to intention to treat. All randomly assigned patients were included in this analysis, not just those who were available for the 5-year toxicity assessment. Details of local recurrences and deaths were obtained from local hospital and cancer registry records. All statistical analyses were performed using STATA statistical software (version 10.1; STATA, College Station, TX).
RESULTS
The late breast tissue toxicity outcomes of 654 (57%) of 1,145 patients (control arm, 237; IMRT arm, 228; non-randomly assigned arm, 189) were available at 5 years. Baseline patient, tumor, and treatment characteristics of the 654 patients are summarized in Table 1 . The characteristics are well balanced between the two randomly assigned arms, with the exception of volume of breast tissue receiving Ͼ 107% of the prescribed dose (as expected). Patients in the non-randomly assigned arm were younger, with smaller tumor size, and less frequently received systemic chemotherapy. The mean breast volume was also significantly larger in the two randomly assigned arms as compared with the non-randomly assigned arm. Reasons for patients with no 5-year assessments from the study are summarized in the CONSORT diagram (Fig 1) .
Five-Year Toxicity in Control (standard RT) Versus Intervention Arm (IMRT)
On univariate analysis, fewer patients in the simple IMRT arm developed suboptimal overall cosmesis (OR, 0.68; 95% CI, 0.48 to 0.96; P ϭ .027) or skin telangiectasia (OR, 0.58; 95% CI, 0.36 to 0.92; P ϭ .021) as compared with the control arm (Table 2 ). However, no significant difference was seen for photographically assessed breast shrinkage (OR, 0.79; 95% CI, 0.55 to 1.14; P ϭ .21), breast edema (OR, 0.74; 95% CI, 0.48 to 1.15; P ϭ .18), tumor bed induration (OR, 0.76; 95% CI, 0.54 to 1.06; P ϭ .11), or pigmentation (OR, 0.80; 95% CI, 0.46 to 1.38; P ϭ .42) between the randomly assigned patients.
On multivariate analysis, the benefits of simple IMRT over standard RT (control arm) were maintained for both overall cosmesis (OR, 0.65; 95% CI, 0.44 to 0.98; P ϭ .038) and skin telangiectasia (OR, 0.57; 95% CI, 0.34 to 0.95; P ϭ .031). Large breast volume (P ϭ .02), poorer baseline surgical cosmesis (P Ͻ .001), and tumor bed boost (P ϭ .003) were also associated with suboptimal overall cosmesis on multivariate analysis. Skin telangiectasia was also associated with older age (P ϭ .005), postoperative breast infection (P Ͻ .001), increasing breast volume (P Ͻ .001), and tumor bed boost (P ϭ .023). The full details of the covariates included in the multivariate analysis are summarized in Appendix Tables A1 and A2 (online only) .
Impact of Pre-RT Surgical Cosmesis on Late Toxicity End Points
Patients with moderate to poor baseline surgical cosmesis more frequently developed suboptimal final cosmesis (OR, 8.15 ; 95% CI, 6.09 to 10.92; P Ͻ .001), tumor bed induration (OR, 1.80; 95% CI, 1.44 to 2.26; P Ͻ .001), and photographically assessed breast shrinkage (OR, 1.54; 95% CI, 1.21 to 1.96; P Ͻ .001) at 5 years in the study.
LRR and OS
There was no statistically significant difference in 5-year LRR and OS rates between the randomly assigned patients (control arm, 404 patients; IMRT arm, 410 patients). The 5-year LRR rates for the control and IMRT arms were 2.56% and 1.35% respectively (P ϭ .36).
The 5-year OS rates for the control and IMRT arms were 92.5% and 91.7%, respectively (P ϭ .88).
DISCUSSION
This large single-center trial confirms that improved dose homogeneity with simple IMRT decreases late breast tissue toxicity. At 5 years, patients receiving simple IMRT had superior overall cosmesis and reduced risk of skin telangiectasia as compared with patients receiving standard RT. However, no significant difference was observed for photographically assessed breast shrinkage or clinically assessed breast edema, breast pigmentation, or breast induration.
To date, only two other randomized trials have compared standard RT with IMRT for early breast cancer. The multicenter Canadian study compared acute toxicity for 331 patients randomly assigned after breast-conservation surgery between IMRT (forward or inverse planned) and standard RT using wedges.
7 Patients in the IMRT arm experienced significantly less moist desquamation during or up to 6 weeks post-RT as compared with standard treatment (31.2% v 47.8%; P ϭ .002). Women of all breast sizes were included in the study, and on multivariate analysis, use of IMRT and small breast size were significantly associated with decreased risk of moist desquamation. Late toxicity has not yet been reported. Donovan et al 5 reported a singlecenter study in which 306 patients were randomly assigned between forward-planned IMRT and standard RT. Of the 240 patients evaluated at 5 years, patients who received standard RT were 1.7ϫ more likely to develop any change in breast appearance on photographic assessment (95% CI, 1.2 to 2.5; P ϭ .008) as compared with patients treated with IMRT. In addition, fewer patients developed palpable induration in the center of the breast, pectoral fold, inframammary fold, and boost site with IMRT. Retrospective case-matched studies have also compared standard RT with IMRT for breast cancer (Appendix Table A3 , online only).
Fewer patients developed breast induration with IMRT in the Donovan et al 5 study; however, a similar reduction in induration was not seen in the interventional arm of the larger Cambridge Breast IMRT trial. The different entry criteria for the two trials may explain these dissimilar results. In the Donovan et al study, women were eligible if they were judged to be at higher than average risk of radiation-induced toxicity based on breast size and/or breast shape. The mean percentages of breast volumes receiving Ͼ 105% of the prescribed dose between standard and IMRT arm were 11.7% versus 1%, respectively. 18 In contrast, women of all breast sizes were eligible for the Cambridge Breast IMRT trial, if their breast volume receiving Ͼ 107% of the prescribed dose was Ն 2 cm 3 on a standard RT plan. The mean percentage of breast volume receiving Ͼ 107% of the prescribed dose was only 2.9% in the control arm of the trial, which decreased to 0⅐6% with IMRT.
12 It is also possible that these dissimilar results resulted from the subjective nature of clinical assessment, with different interpretation of induration between clinicians of the two studies.
Our study found tumor bed boost to be an independent risk factor for suboptimal cosmesis and skin telangiectasia, as previously shown in the EORTC (European Organisation for Research and Treatment of Cancer) 22881-10882 boost-versus-no boost trial. 19 Large-breasted women more frequently develop late breast tissue toxicity, and this has been linked to their suboptimal dosimetry. 20 Our study found large breast volume to be a risk factor for suboptimal cosmesis and skin telangiectasia, independent of dose inhomogeneity. Similar results were also seen in the UK FAST hypofractionated trial at 2 years. 21 The FAST Trialists group postulated that in large-breasted women, the major component of the breast is adipose tissue, which is perhaps more sensitive to the effects of RT and hence more likely to develop late toxicity. However, one should also note that in postmenopausal patients, the major component of the breast is usually adipose tissue regardless of breast size.
Our study also highlights the importance of optimal surgical cosmesis, because patients with moderate to poor surgical cosmesis are more likely to develop breast shrinkage, breast induration, and suboptimal final cosmesis.
The local control and survival rates with both standard RT and IMRT are excellent. It is generally accepted that simple IMRT, which removes regions of high radiation dose should not affect local control and/or survival rates. Therefore, this trial was not intended to detect a difference in local control and/or survival rates between standard RT and IMRT. However, it has been postulated that removing hotspots with IMRT can lead to dose de-escalation, especially to the skin, and a theoretic increased risk of local relapse. 22 At 5 years, there was no statistical difference in LRR and OS rates between the randomly assigned patients of the study.
Our study has some limitations. A significant number of patients were withdrawn from the 5-year analysis. The routine clinical follow-up of patients post-RT was based at their regional referring hospitals, and many patients turned down their 5-year trial appointment at Cambridge because of travel difficulties, social issues, or personal choice (Fig 1) . Patients were also withdrawn from the analysis because of cancer-related factors, including local or systemic relapse, new cancer, or death. The referral hospitals were contacted for information on LRR, metastasis, and survival, but data on late breast tissue toxicity were not available routinely.
In conclusion, the 5-year results from this study are practice changing. Improved dose homogeneity with simple IMRT translates into superior overall cosmesis and reduces the risk of skin telangiectasia 5 years after breast RT. Although breast IMRT has been implemented by many centers, there has not been universal adoption of this technique to date. This study should act as an evidence-based lever for change for RT centers that have yet to implement breast IMRT. In addition, surgical cosmesis should be optimized before RT delivery, becuase this also has a significant effect on late breast toxicity and overall cosmesis.
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